zzf
Lv2
180 积分
2024-12-10 加入
-
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
22天前
已完结
-
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
22天前
已完结
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
22天前
已完结
-
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
25天前
已完结
-
Glucagon‐like peptide‐1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity
26天前
已完结
-
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
1个月前
已完结
-
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
1个月前
已完结
-
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
1个月前
已完结
-
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
8个月前
已完结